- Works count
- 682
- Citation count
- 14,394
- H-index
- 57
- i10-index
- 300
Research interests
Publications
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial
The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32534-6
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)31946-9
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Annals of the Rheumatic Diseases · 2018 · https://doi.org/10.1136/annrheumdis-2018-213328
High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry
Nature Genetics · 2016 · https://doi.org/10.1038/ng.3496
Hypoxia‐enhanced wound‐healing function of adipose‐derived stem cells: Increase in stem cell proliferation and up‐regulation of VEGF and bFGF
Wound Repair and Regeneration · 2009 · https://doi.org/10.1111/j.1524-475x.2009.00499.x
Current projects
No projects listed.